

Contents

| | |
|---|-----|
| Foreword (For First Edition) | vii |
| Acknowledgements | ix |
| Abbreviations | xxi |
| 1 Brief History of Clinical Dialysis: The Seattle Experience | 1 |
| 1.1 Definition of Dialysis | 3 |
| 1.2 Mechanisms Involved in Molecular Movement | 3 |
| 1.2.1 Diffusion | 4 |
| 1.2.2 Ultrafiltration | 4 |
| 1.2.3 Osmosis | 5 |
| 1.2.4 Convection | 5 |
| 1.3 Clearance | 5 |
| 1.3.1 Blood vs Plasma Clearance | 6 |
| 1.3.2 Clinical Factors Influencing Dialysis Urea Clearance | 6 |
| Reference | 6 |
| 2 Hemodialysis Technique | 7 |
| 2.1 Blood Flow Rate | 7 |
| 2.2 Dialysate Flow Rate | 7 |
| 2.3 Dialyzer Efficiency and Mass Transfer Area Coefficient (KoA) | 8 |
| 2.4 Different Hemodialysis Techniques | 8 |
| 2.4.1 Traditional Hemodialysis | 8 |
| 2.4.2 Hemofiltration | 9 |
| 2.4.3 Hemodiafiltration | 10 |
| 2.4.4 Slow Low Efficiency Dialysis (SLED) | 10 |
| 2.4.5 Ultrafiltration | 10 |
| 2.5 Hemodialysis Setup | 10 |
| 2.5.1 Blood Circuit | 11 |
| 2.5.2 Dialysate Circuit | 18 |
| References | 27 |

| | | |
|----------|--|----|
| 3 | Anticoagulation | 29 |
| 3.1 | Heparin Anticoagulation | 30 |
| 3.1.1 | Systemic Standard Heparinization | 31 |
| 3.1.2 | Low-Dose Heparinization | 31 |
| 3.1.3 | Low Molecular Weight Heparin | 31 |
| 3.2 | Problems with Heparin Anticoagulation | 32 |
| 3.3 | Alternatives to Heparin | 33 |
| 3.3.1 | Citrate Anticoagulation | 33 |
| 3.4 | No Anticoagulation | 35 |
| | References | 36 |
| 4 | Vascular Access | 37 |
| 4.1 | Permanent Access | 37 |
| 4.1.1 | Preparation | 37 |
| 4.1.2 | Arteriovenous Fistula | 38 |
| 4.1.3 | Arteriovenous Graft | 41 |
| 4.1.4 | Diagnosis and Management of Arteriovenous Dialysis Access | 43 |
| 4.1.5 | Dual-Lumen Catheters with Dacron Cuff | 45 |
| 4.1.6 | Special Arteriovenous Shunts | 48 |
| 4.2 | Temporary Access | 49 |
| 4.2.1 | General Technique | 50 |
| 4.2.2 | Complications of Temporary Access | 52 |
| 4.2.3 | Comparison of the Three Access Sites | 55 |
| 4.3 | Impact of Access | 55 |
| 4.3.1 | Access Surveillance | 56 |
| | References | 58 |
| 5 | Complications of Hemodialysis | 59 |
| 5.1 | Medical Complications | 59 |
| 5.1.1 | Hypotension | 59 |
| 5.1.2 | Cardiac Arrhythmias | 68 |
| 5.1.3 | Intradialytic Hypertension | 69 |
| 5.1.4 | Muscle Cramps | 69 |
| 5.1.5 | Carnitine and Intradialytic Hypotension, Arrhythmias, and Muscle Cramps | 70 |
| 5.1.6 | Nausea and Vomiting | 71 |
| 5.1.7 | Headache | 71 |
| 5.1.8 | Serious, Less Common Complications | 72 |
| 5.2 | Machine-Related Complications | 75 |
| 5.2.1 | Air Embolism | 75 |
| 5.2.2 | Hemolysis | 76 |
| | References | 76 |

| | |
|--|-----|
| Contents | xv |
| 6 Dose of Hemodialysis | 79 |
| 6.1 Historical Background | 79 |
| 6.1.1 Dialysis Index | 80 |
| 6.1.2 Urea Clearance | 80 |
| 6.1.3 Urea as a Marker for Uremic Toxins | 81 |
| 6.1.4 Current Methods of Measuring Dialysis Dose | 81 |
| 6.2 Potential Problems with the Calculation of Dialysis Dose | 83 |
| 6.2.1 Influence of the Single-Pool Model | 83 |
| 6.3 Determining Adequate Dialysis | 91 |
| 6.3.1 Acceptable Kt/V Values | 92 |
| 6.3.2 Frequency of Dose Measurement | 92 |
| References | 92 |
| 7 Continuous Therapies | 95 |
| 7.1 Overview | 95 |
| 7.2 Types of Continuous Therapies | 95 |
| 7.2.1 Continuous Arteriovenous Hemofiltration (CAVH) | 95 |
| 7.2.2 Continuous Venovenous Hemofiltration (CVVH)..... | 96 |
| 7.2.3 Continuous Venovenous Hemodialysis (CVVHD) | 98 |
| 7.2.4 Continuous Venovenous Hemodiafiltration (CVVHDF) | 99 |
| 7.2.5 Slow Low-Efficiency Diffusion Hemodialysis (SLEDD).... | 99 |
| 7.2.6 Slow Continuous Ultrafiltration (SCUF) | 100 |
| 7.2.7 Newer Technologies..... | 100 |
| 7.3 Components of Continuous Therapies | 102 |
| 7.3.1 Vascular Access | 102 |
| 7.3.2 Tubing | 103 |
| 7.3.3 Filter | 104 |
| 7.3.4 Replacement Fluid | 104 |
| 7.3.5 Dialysis Fluid | 109 |
| 7.3.6 Machines | 110 |
| 7.4 Dialysate Flow and Ultrafiltration Rates | 110 |
| 7.5 Anticoagulation | 112 |
| 7.5.1 Heparin | 113 |
| 7.5.2 Low Molecular Weight Heparin | 113 |
| 7.5.3 Citrate | 113 |
| 7.5.4 Prostacyclin | 114 |
| 7.5.5 Argatroban | 115 |
| 7.5.6 Lepirudin | 115 |
| 7.5.7 Danaparoid | 115 |
| 7.5.8 Fondaparinux | 116 |
| 7.5.9 Nafamostat | 117 |
| 7.5.10 No Anticoagulation | 117 |
| 7.6 Drug Removal During CRRT..... | 117 |

| | | |
|-----------|---|-----|
| 7.7 | Intraoperative Dialysis | 118 |
| 7.8 | Dose of Dialysis in Continuous Therapies | 119 |
| | References | 120 |
| 8 | Peritoneal Dialysis | 123 |
| 8.1 | Historical Background | 123 |
| 8.2 | Anatomy and Physiology | 123 |
| 8.3 | Kinetics of Peritoneal Transport | 125 |
| 8.3.1 | Diffusion | 125 |
| 8.3.2 | Ultrafiltration | 126 |
| | References | 127 |
| 9 | Technique of Peritoneal Dialysis | 129 |
| 9.1 | Peritoneal Dialysis Catheters | 129 |
| 9.1.1 | Description | 129 |
| 9.1.2 | Catheter Insertion Technique | 131 |
| 9.2 | Peritoneal Dialysis Fluid | 137 |
| 9.2.1 | Osmotic Agents | 137 |
| 9.3 | Delivery Mechanism | 140 |
| 9.4 | Peritoneal Dialysis Techniques | 140 |
| 9.4.1 | Continuous Ambulatory Peritoneal Dialysis (CAPD) | 140 |
| 9.4.2 | Automated Peritoneal Dialysis (APD) | 140 |
| | References | 143 |
| 10 | Dose of Peritoneal Dialysis | 145 |
| 10.1 | Weekly Creatinine Clearance | 145 |
| 10.1.1 | Residual Glomerular Filtration Rate | 146 |
| 10.1.2 | Peritoneal Creatinine Clearance | 146 |
| 10.1.3 | Correction for Body Surface Area | 147 |
| 10.1.4 | Total Weekly Creatinine Clearance Calculation | 148 |
| 10.2 | Urea Clearance Concept (Kt/V_{urea}) | 148 |
| 10.2.1 | Volume of Distribution of Urea | 148 |
| 10.3 | Recommended Dose of Dialysis | 149 |
| 10.3.1 | Potential Problem with Dose Measurements | 150 |
| 10.3.2 | Frequency of Dose Determination | 150 |
| 10.4 | Peritoneal Function Test | 151 |
| 10.4.1 | Traditional Peritoneal Equilibration Test | 151 |
| 10.4.2 | Fast Peritoneal Equilibration Test | 151 |
| 10.4.3 | Results of the Peritoneal Equilibration Test | 152 |
| 10.5 | Use of Fast Peritoneal Equilibration Test Results in Selecting a Peritoneal Dialysis Regimen | 153 |
| 10.5.1 | Selection of Technique | 154 |
| | References | 155 |

| | |
|--|-----|
| 11 Complications of Peritoneal Dialysis | 157 |
| 11.1 Peritonitis | 157 |
| 11.1.1 Clinical Diagnosis | 157 |
| 11.1.2 Therapy | 160 |
| 11.2 Exit Site and Tunnel Infection (also see Chapter 9) | 165 |
| 11.3 Under-dialysis | 165 |
| 11.4 Malnutrition | 166 |
| 11.5 Membrane Failure | 166 |
| 11.6 Cardiovascular Complications | 166 |
| 11.7 Intra-Abdominal Pressure | 167 |
| 11.8 Hemoperitoneum | 167 |
| References | 167 |
| 12 Nutritional Issues | 169 |
| 12.1 Protein Calorie and Nutritional Status of Dialysis Patients | 169 |
| 12.2 Significance of Nutritional Status | 170 |
| 12.2.1 Hemodialysis | 170 |
| 12.2.2 Peritoneal Dialysis | 170 |
| 12.3 Factors Causing Malnutrition | 172 |
| 12.3.1 Uremia | 172 |
| 12.3.2 Other Factors | 172 |
| 12.4 Assessment of Nutritional Status | 173 |
| 12.4.1 Dietary Intake | 173 |
| 12.4.2 Anthropometry and Body Weights | 175 |
| 12.4.3 Bioelectric Impedance Analysis | 175 |
| 12.4.4 Dual Energy X-Ray Absorptiometry | 175 |
| 12.4.5 Subjective Global Assessment | 175 |
| 12.4.6 Biochemical Assessment | 176 |
| 12.5 Nutritional Requirements | 176 |
| 12.5.1 Protein | 178 |
| 12.5.2 Caloric Intake | 178 |
| 12.5.3 Lipids | 178 |
| 12.5.4 Fatty Acids, Lipids, and Carnitine | 178 |
| 12.5.5 Vitamins and Trace Elements | 179 |
| 12.5.6 Additional Nutritional Support | 180 |
| 12.5.7 Metabolic Acidosis | 180 |
| References | 181 |
| 13 Hypertension | 183 |
| 13.1 Prevalence | 183 |
| 13.2 Control of Hypertension | 183 |
| 13.3 Significance of Hypertension Control | 186 |
| 13.4 Pathogenesis | 186 |
| 13.4.1 Sodium Excess | 187 |
| 13.4.2 Other Factors | 188 |

| | | |
|-----------|---|------------|
| 13.5 | Treatment of Hypertension | 188 |
| 13.5.1 | Sodium and Volume Control | 188 |
| 13.5.2 | Ultrafiltration | 190 |
| 13.5.3 | Pharmacological Agents | 192 |
| 13.6 | Conclusions | 197 |
| | References | 197 |
| 14 | Anemia | 199 |
| 14.1 | Pathogenesis | 199 |
| 14.1.1 | Erythropoietin | 199 |
| 14.1.2 | Uremic Factors | 200 |
| 14.1.3 | Other Factors | 201 |
| 14.2 | Treatment of Anemia | 201 |
| 14.2.1 | Erythropoietin-Stimulating Agents (ESA) and Administration | 201 |
| 14.3 | Iron Status | 205 |
| 14.3.1 | Tests to Evaluate Iron Status | 205 |
| 14.3.2 | Iron Supplementation | 206 |
| 14.4 | Carnitine | 207 |
| 14.5 | Other Measures to Improve Hematocrit Response | 208 |
| | References | 208 |
| 15 | Renal Osteodystrophy | 211 |
| 15.1 | Pathophysiology of Renal Osteodystrophy | 211 |
| 15.1.1 | Vitamin D Metabolism | 211 |
| 15.1.2 | Phosphorus Retention | 212 |
| 15.1.3 | Parathyroid Hormone | 212 |
| 15.2 | Histological Classification of Renal Osteodystrophy | 214 |
| 15.2.1 | High-Turnover Bone Disease | 215 |
| 15.2.2 | Low-Turnover Bone Disease | 215 |
| 15.2.3 | Mixed (Uremic) Bone Disease | 216 |
| 15.3 | Clinical Manifestation of Renal Osteodystrophy | 216 |
| 15.4 | Metastatic Calcification | 217 |
| 15.5 | Laboratory Findings and Management of ROD | 218 |
| 15.5.1 | Laboratory Findings | 218 |
| 15.5.2 | High Turnover Disease | 221 |
| 15.6 | Low-Turnover Disease | 224 |
| 15.6.1 | Aluminum Control | 224 |
| 15.6.2 | Low Parathyroid Hormone | 224 |
| 15.6.3 | Other Therapies | 224 |
| 15.6.4 | Prevention | 225 |
| | References | 225 |

| | |
|--|-----|
| 16 Atypical Dialysis Circumstances | 227 |
| 16.1 Pregnancy | 227 |
| 16.1.1 Dialysis | 227 |
| 16.1.2 Associated Conditions | 229 |
| 16.2 Drug Removal in Overdose Situations | 229 |
| 16.2.1 Peritoneal Dialysis | 230 |
| 16.2.2 Hemodialysis | 230 |
| 16.2.3 Hemoperfusion | 230 |
| 16.2.4 Specific Examples | 231 |
| Reference | 232 |
| 17 The Future | 233 |
| 17.1 Increasing Financial Pressure | 233 |
| 17.2 Changing Population | 233 |
| 17.3 Patient Outcome Measures | 233 |
| 17.4 Limited Transplantation Options | 234 |
| 17.5 Low Rates of Rehabilitation | 234 |
| 17.6 Ideal Renal Replacement Therapy | 234 |
| 17.7 Simpler Machines and Daily Dialysis | 235 |
| 17.7.1 Diffusion vs Convection | 235 |
| 17.8 Mechanical Artificial Kidney | 235 |
| 17.8.1 Implantable Mechanical, Artificial Kidney | 236 |
| Reference | 237 |
| Index | 239 |